Since the mortality rates five years after many solid organ transplants are similar to the mortality rates five years after the first diagnosis of many common cancers, new therapeutic strategies for transplant recipients are desperately needed. While academia continues to produce the basic knowledge required to discover and develop more effective, safer and more cost-effective therapeutics, industry and academia must work together to conduct the clinical trials required for regulatory approval of improved therapeutics. Despite the current unmet clinical need for improved therapeutics, there is a gap in needed expertise and new approaches between where basic science ends and where later stages of clinical trial development begin. Solutions to bridge this gap will be proposed suggesting that the answer to the question is that academia, industry as well as new organizations that bridge this gap are all needed for the creation of new therapeutics.
Stanford University School of Medicine
You must be logged in and own this session in order to